


Boosting Europe's competitiveness and scientific leadership



EDCTP's added
value for Europe



EDCTP strengthens Europe's competitiveness by fostering research excellence and global cooperation to advance health innovations.

EDCTP's geographical and technological scope opens opportunities for European companies to expand into new markets and contribute to global health solutions.



Scan
for more
info

EDCTP's added value for Europe

Protecting Europe through stronger global health security cooperation



EDCTP's added
value for Europe



EDCTP contributes to Europe's health security by addressing climate-sensitive infectious disease threats and antimicrobial resistance.


EDCTP has also demonstrated exceptional agility in responding to health crises and outbreaks.



Scan
for more
info

EDCTP's added value for Europe

Spearheading Europe's science diplomacy through equitable partnerships



EDCTP's added
value for Europe



EDCTP is the largest and most established research partnership between Europe and Africa.

EDCTP's funding and governance are based on joint Africa-Europe ownership.

EDCTP ensures that research consortia operate equitably and uphold high ethical scientific standards.



Scan
for more
info

EDCTP's added value for Europe

Leveraging Europe's digital talent for public health solutions



EDCTP's added
value for Europe



EDCTP reinforces Europe's strategic leadership for digital transformation and smarter responses to health challenges by investing in digital and AI technologies in health.

EDCTP also advances the implementation of key international strategies in digital health transformation.

EDCTP creates collaboration and investment opportunities for European companies by supporting digital capacity and innovation in Africa.



Scan
for more
info

EDCTP's added value for Europe

Advancing Europe's human rights commitment at the global and local levels



EDCTP's added
value for Europe



EDCTP contributes to the EU's commitment to human rights by addressing unmet medical needs, promoting gender equality and research equity, and delivering life-saving health technologies for vulnerable populations.


EDCTP promotes an inclusive innovation ecosystem and prioritises ethical research that responds to historically neglected populations.



Scan
for more
info

EDCTP's added value for Europe

Boosting Africa's prosperity through better health and wellbeing



EDCTP's added
value for Africa



EDCTP is dedicated to reducing Africa's infectious disease burden by funding clinical research and strengthening local capacity.


EDCTP strengthens African health research systems and empowers local professionals to tackle the continent's health priorities.



Scan
for more
info

EDCTP's added value for Africa

Contributing to Africa's health security and sovereignty



EDCTP's added
value for Africa



EDCTP contributes to Africa's health security by supporting clinical research, training, and networks for epidemic preparedness and response.

EDCTP supports Africa's response to health threats, including Ebola, mpox, COVID-19, Lassa fever, and climate change- and AMR-related outbreaks.



Scan
for more
info

EDCTP's added value for Africa

Enhancing Africa's clinical research ecosystems



EDCTP's added
value for Africa



Boosting clinical research across the continent is key to improving health outcomes and social and economic development. EDCTP has enhanced clinical research ecosystems in Africa by supporting over 3,000 researchers and health professionals.

EDCTP has supported the establishment of the Pan African Clinical Trials Registry (PACTR), which became a WHO Primary Clinical Trials Registry.



Scan
for more
info

EDCTP's added value for Africa

Advancing health partnerships within Africa and with Africa



EDCTP's added
value for Africa



EDCTP advances health partnerships in Africa by aligning research, investments and interventions with the continent's priorities.

As a key implementing partner of the European Union–African Union Innovation Agenda, EDCTP helps align policy, research and innovation systems between Europe and Africa.



Scan
for more
info

EDCTP's added value for Africa

Driving health equity and trust in Africa



EDCTP's added
value for Africa



EDCTP drives health equity by prioritising underserved populations - including women, newborns and children, poor people and rural communities - helping accelerate Africa's progress towards Universal Health Coverage.

Equity and trust guide EDCTP's work: research and resulting technologies are required to be accessible, acceptable, and gender-responsive, developed with high ethical standards and active community participation.



Scan
for more
info

EDCTP's added value for Africa

The first-ever malaria vaccines

**European
Medicines
Agency's
positive opinion**

**WHO-
recommended
treatment**



EDCTP's support for this medicine included:

- Funding for research & development
- Capacity & infrastructure building
- Support for regulatory approval & policy improvement
- Funding for further innovation & optimisation

New and better medicines already
saving and improving lives

What it is

RTS,S and R21/Matrix-M are the first vaccines against malaria and, more broadly, against any parasitic disease. Both vaccines stimulate an immune response that prevents malaria infection.

Why it matters

Global immunisation is among the most effective interventions to prevent infant mortality and severe disease. Each year, over 150 million children contract malaria, and around 500,000 die. These vaccines could prevent millions of illnesses and save thousands of children every year.




Scan
for more
info

New and better medicines

A unique medicine for worm infections in children

**European
Medicines
Agency's
positive opinion**

**WHO-
recommended
treatment**



EDCTP's support for this medicine included:

- Funding for research & development
- Support for regulatory approval & policy improvement
- Facilitating access & rollout
- Funding for further innovation & optimisation

New and better medicines already
saving and improving lives



What it is

This new fixed-dose combination therapy of albendazole/ivermectin targets five types of parasitic worms (four soil-transmitted helminth infections and lymphatic filariasis), which will significantly improve the efficiency and cost-effectiveness of large-scale interventions.

Why it matters

Soil-transmitted helminths and lymphatic filariasis are neglected diseases affecting one in four people worldwide and leaving children nutritionally and physically impaired. This new treatment will enhance the effectiveness of public health interventions against these parasites, benefiting millions worldwide.



Scan
for more
info

New and better medicines

Groundbreaking innovations to protect children and mothers from malaria

European Medicines Agency's positive opinion

WHO-recommended treatment



EDCTP's support for this medicine included:

- Funding for research & development
- Support for regulatory approval & policy improvement
- Funding for further innovation & optimisation

New and better medicines already saving and improving lives

What it is

Coartem® Baby and Pyramax®'s new formulations for children and pregnant women are safe and effective against malaria and better suited to their specific needs.

Why it matters

Malaria is life-threatening for unborn babies and children under five and a leading cause of child mortality in Africa. These safer and more acceptable medicines will better protect children from this threat.



Scan
for more
info

New and better medicines

The first medicine against schistosomiasis for pre-school children

**European
Medicines
Agency's
positive opinion**

**WHO-
recommended
treatment**



EDCTP's support for this medicine included:

- Funding for research & development
- Support for regulatory approval & policy improvement
- Facilitating access & rollout
- Funding for further innovation & optimisation

New and better medicines already
saving and improving lives

What it is

Arpraziquantel is the first child-friendly medicine in an oro-dispersible formulation to treat and cure schistosomiasis. It is easy to administer and adapted for rural and tropical settings, offering high efficacy with minimal side effects.

Why it matters

Schistosomiasis affects around 240 million people worldwide and severely harms children's physical and cognitive development. This innovation could protect and improve the lives of 50 million children currently at risk.




Scan
for more
info

New and better medicines

A patient-friendly medicine for sleeping sickness

**European
Medicines
Agency's
positive opinion**

**WHO-
recommended
treatment**



EDCTP's support for this medicine included:

- Funding for research & development
- Support for regulatory approval & policy improvement
- Funding for further innovation & optimisation

New and better medicines already
saving and improving lives



What it is

Fexinidazole is the first all-oral treatment for sleeping sickness. Taken as simple pills over 10 days, it eliminates the need for hospitalisation and painful lumbar punctures, and has become the most widely used therapy for this disease.

Why it matters

Although sleeping sickness is nearing eradication, it persists in the poorest and most remote areas of Africa, where delivering care is a significant challenge. The disease is usually fatal without treatment, making this patient-friendly innovation essential.




Scan
for more
info

New and better medicines

A simpler treatment for HIV-associated cryptococcal meningitis

WHO-
recommended
treatment



EDCTP's support for this treatment included:

- Funding for research & development
- Support for regulatory approval & policy improvement
- Funding for further innovation & optimisation

New and better medicines already
saving and improving lives

What it is

This new therapy, a single high-dose of liposomal Amphotericin B, is as effective as the traditional week-long regimen, easier to administer, and causes fewer side effects. It is now the WHO-recommended therapy for cryptococcal meningitis.

Why it matters

Despite highly effective HIV treatments, opportunistic infections such as cryptococcal meningitis continue to cause significant morbidity and mortality, accounting for around 200,000 AIDS-related deaths annually. This new therapy can help save lives and improve the health of people living with HIV.



Scan
for more
info

New and better medicines

Ensuring children have appropriate HIV treatment



EDCTP's support for this medicine included:

- Funding for research & development
- Support for regulatory approval & policy improvement
- Funding for further innovation & optimisation

New and better medicines already
saving and improving lives

What it is

Triomune Baby/Junior became the first fixed-dose combination medicine developed specifically for children with HIV and paved the way for additional improved combination therapies for first- and second-line HIV treatment in children.

Why it matters

While antiretroviral therapy (ART) is lifesaving against HIV, existing formulations are often unsuitable for babies and children. These innovations enhance the acceptability and use of ART in children, helping to save and improve their lives.



Scan
for more
info

New and better medicines

Fast, effective, and easy-to-use treatment for uncomplicated malaria

**European
Medicines
Agency
approved**

**WHO-
recommended
treatment**



EDCTP's support for this medicine included:

- Support for regulatory approval & policy improvement
- Funding for further innovation & optimisation

New and better medicines already
saving and improving lives

What it is

Dihydroartemisinin-piperaquine (DHAPQ) is an artemisinin-based combination therapy (ACT) used to treat uncomplicated malaria. This combination provides a simple three-day regimen that is highly effective and reduces the risk of recurrent infections.

Why it matters

It helps address critical gaps in malaria treatment by providing a well-tolerated, easy-to-administer therapy that reduces both treatment failure and reinfection rates. It is suitable for children, who remain among the most vulnerable to malaria.



Scan
for more
info

New and better medicines